GLAUKOS Corp GKOS
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
0.74
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $507.4M | -$187.7M | $282.8M | -$22.5M | $656.2M |
| 2024 | $383.5M | -$146.4M | $289.5M | -$67.6M | $766.9M |
| 2023 | $314.7M | -$134.7M | $239.1M | -$78.0M | $461.8M |
| 2022 | $282.9M | -$99.2M | $213.9M | -$63.3M | $530.0M |
| 2021 | $294.0M | -$49.6M | $227.4M | -$23.1M | $587.2M |
| 2020 | $225.0M | -$120.3M | $133.2M | -$29.9M | $667.4M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.74 (distress)
- Working capital / assets 0.418
- Retained earnings / assets -1.044
- EBIT / assets -0.223
- Equity / liabilities 2.765
Source: SEC EDGAR filings · CIK 0001192448 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.